Category Archives: Global News Feed

Double-Blind, Peer-Reviewed Study Presented at 2022 ACSM Annual Meeting Double-Blind, Peer-Reviewed Study Presented at 2022 ACSM Annual Meeting

See the original post here:
Healthy Extracts New Clinical Study Highlights UBN RELIEF Naturally Alleviates Migraine Symptoms

– Five abstracts accepted, long-term data confirmed durable efficacy with Bylvay™ (odevixibat), with demonstrated improvement in quality of life, growth, and sleep measurements, and hepatic biomarkers in children with all types of PFIC

Originally posted here:
Albireo to Present New Data at the EASL International Liver Congress™ 2022

Meeting adjourned to July 6, 2022 at 9:30 a.m. PT

See the rest here:
Vaxart Announces Adjournment of Annual Meeting of Stockholders

Media ReleaseCOPENHAGEN, Denmark; June 8, 2022Genmab A/S (Nasdaq: GMAB) announced today that its Chief Financial Officer Anthony Pagano and Chief Development Officer Judith Klimovsky will participate in a fireside chat at the Goldman Sachs 43rd Annual Global Healthcare Conference in Rancho Palos Verdes, California 1:20 PM PDT on June 15, 2022 (4.20 PM EDT / 10.20 PM CEST). A webcast of the fireside chat will be available on Genmab’s website at https://ir.genmab.com/events-and-presentations#content

Go here to see the original:
Genmab to Participate in a Fireside Chat at the Goldman Sachs 43rd Annual Global Healthcare Conference

BOSTON, June 08, 2022 (GLOBE NEWSWIRE) -- Cerevance, a private, clinical-stage drug discovery and development company focused on central nervous system (CNS) diseases, today announced that Craig Thompson, chief executive officer of Cerevance, will participate in a panel discussion during the 2022 BIO International Convention being held in San Diego, CA, June 13-16. Mr. Thompson will present at the panel titled, “CNS drug development: Do biomarkers hold the future for patients?” and will share his insights on the future of neurological drug development alongside other leading CNS experts in the life sciences industry.

See the article here:
Cerevance to Participate in Panel Discussion During the 2022 BIO International Convention

ROCKVILLE, MD, June 08, 2022 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following investor conference in June 2022:

Go here to see the original:
MacroGenics to Participate in Upcoming Investor Conference